糖皮龙胺与安尼索达胺胺在预防恶心和吐以及在ERCP后缓解的作用:一项随机对照试验
Qingjing Ma1, Dina Sun2, Yan Rao1
1Department of Anesthesiology, The Second Affiliated Hospital, Chongqing University of Medical Science, Chongqing, China.
糖皮隆胺在内镜逆行胆瘤学术 (ERCP) 后有效地预防手术后恶心和吐 (PONV). 这种抗胆固醇药物提供类似于安尼索达胺酸的缓解,但PONV率明显较低.
科学领域:
- 麻醉学 麻醉学
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 手术后的恶心和吐 (PONV) 是在全身麻醉下进行内镜逆行胆血管细胞造影 (ERCP) 后的常见并发症.
- 作为一种抗胆固醇药物,糖皮龙胺被认为具有减轻胃肠和预防PONV的潜力.
研究的目的:
- 为了比较糖皮龙化与安尼索达胺化在预防PONV方面的疗效.
- 在ERCP期间评估这两种药物的缓解效果.
主要方法:
- 一个单一的前性研究,涉及130名接受ERCP的患者.
- 随机分配患者接受静脉注射糖皮龙胺 (0.2毫克) 或肌内注射安尼索达胺胺 (10毫克).
- 评估了十二指肠运动性和手术后24小时内PONV的发病率.
主要成果:
- 恶心和吐的发生率在糖皮龙化组 (13.8%) 与安尼索达胺酸组 (29.2%) (p=0.033) 相比,在糖皮龙化组明显较低.
- 具体来说,吐发生的频率较少在糖皮龙酸组 (4.6%) 与安尼索达胺酸组 (18.5%) (p=0.028) 相比.
- 两组之间没有观察到十二指管周平静的显著差异.
结论:
- 糖皮隆 (0.2毫克静脉注射) 在接受ERCP全身麻醉的患者中显著降低了PONV.
- 糖皮龙酸的抗效应与酸 (10 mg IM) 的抗效应相当.
- 糖皮隆化物是ERCP患者PONV预防的可行选择.
更多相关视频
08:50How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants
Published on: December 14, 2014
14:52Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers
Published on: January 13, 2018
相关概念视频
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Skeletal Muscle Relaxants: Therapeutic Uses
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Endoscopic Procedures V: ERCP
Patient...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
